CA2735970A1 - Isatin derivatives for use as in vivo imaging agents - Google Patents

Isatin derivatives for use as in vivo imaging agents Download PDF

Info

Publication number
CA2735970A1
CA2735970A1 CA2735970A CA2735970A CA2735970A1 CA 2735970 A1 CA2735970 A1 CA 2735970A1 CA 2735970 A CA2735970 A CA 2735970A CA 2735970 A CA2735970 A CA 2735970A CA 2735970 A1 CA2735970 A1 CA 2735970A1
Authority
CA
Canada
Prior art keywords
compound
compounds
caspase
optionally substituted
isatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2735970A
Other languages
English (en)
French (fr)
Inventor
Eric Ofori Aboagye
Graham Smith
Quang-De Nguyen
Erik Arstad
Matthias Eberhard Glaser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hammersmith Imanet Ltd
Ip2ipo Innovations Ltd
Original Assignee
Imperial Innovations Ltd
Hammersmith Imanet Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0816294A external-priority patent/GB0816294D0/en
Priority claimed from GB0818076A external-priority patent/GB0818076D0/en
Application filed by Imperial Innovations Ltd, Hammersmith Imanet Ltd filed Critical Imperial Innovations Ltd
Publication of CA2735970A1 publication Critical patent/CA2735970A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2735970A 2008-09-05 2009-09-04 Isatin derivatives for use as in vivo imaging agents Abandoned CA2735970A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0816294A GB0816294D0 (en) 2008-09-05 2008-09-05 Compounds
GB0816294.3 2008-09-05
GB0818076.2 2008-10-02
GB0818076A GB0818076D0 (en) 2008-10-02 2008-10-02 Compounds
PCT/GB2009/002132 WO2010026388A1 (en) 2008-09-05 2009-09-04 Isatin derivatives for use as in vivo imaging agents

Publications (1)

Publication Number Publication Date
CA2735970A1 true CA2735970A1 (en) 2010-03-11

Family

ID=41181051

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2735970A Abandoned CA2735970A1 (en) 2008-09-05 2009-09-04 Isatin derivatives for use as in vivo imaging agents

Country Status (10)

Country Link
US (1) US8961930B2 (https=)
EP (1) EP2367816B1 (https=)
JP (1) JP5667056B2 (https=)
KR (1) KR20110066927A (https=)
CN (1) CN102171208A (https=)
AU (1) AU2009289062B2 (https=)
CA (1) CA2735970A1 (https=)
MX (1) MX2011002498A (https=)
RU (1) RU2535975C2 (https=)
WO (1) WO2010026388A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103687627A (zh) 2011-03-01 2014-03-26 通用电气健康护理有限公司 作为pet示踪剂的放射性标记的奥曲肽酸类似物
GB201121911D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Radiofluorination method
CN103183631B (zh) * 2011-12-28 2016-08-24 天津市国际生物医药联合研究院 靛红-5-磺酰胺类衍生物及其在制备治疗非典型性肺炎的药物中的应用
WO2017193180A1 (pt) * 2016-05-10 2017-11-16 Fundação Oswaldo Cruz (Fiocruz) - Superintendência De Planejamento Compostos derivados de isatina, uso dos compostos no tratamento de aids e método de tratamento usando ditos compostos
CN115171929B (zh) * 2021-04-01 2024-07-16 中核核电运行管理有限公司 重水堆机组给水支管与燃料通道小间隙问题处理的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1240648A (en) 1967-08-16 1971-07-28 Wyeth John & Brother Ltd N-substituted isatins
AR016384A1 (es) 1997-07-30 2001-07-04 Smithkline Beecham Corp Inhibidores de caspasas, composiciones farmaceuticas que comprenden dichos inhibidores de caspasas y uso de los inhibidores de caspasas para prepararun medicamento util para el tratamiento de apoptosis y desordenes asociados con excesiva actividad de la convertosa il-1 beta.
WO2001022966A1 (en) 1999-09-30 2001-04-05 Smithkline Beecham Corporation Caspases and apoptosis
SI1255752T1 (sl) * 2000-02-15 2007-12-31 Pharmacia & Upjohn Co Llc S pirolom substituirani zaviralci 2-indolinon protein kinaza
RU2259999C2 (ru) * 2003-08-26 2005-09-10 ООО "Исследовательский институт химического разнообразия" 1-сульфонил-1,3-дигидроиндол-2-оны, фармацевтические композиции (варианты), способ их получения и применения
GB0327494D0 (en) 2003-11-26 2003-12-31 Amersham Plc Novel imaging agents
US7270799B2 (en) 2004-01-15 2007-09-18 Nst Neurosurvival Technologies Ltd. Perturbed membrane-binding compounds and methods of using the same
US7256198B2 (en) * 2004-02-18 2007-08-14 Wyeth Pyrimidoindolones and methods for using same
GB0428012D0 (en) 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods
WO2006074799A2 (en) * 2005-01-17 2006-07-20 Universitätsklinikum Münster 5-pyrrolidinylsulfonyl isatin derivatives

Also Published As

Publication number Publication date
RU2011112075A (ru) 2012-10-10
EP2367816A1 (en) 2011-09-28
RU2535975C2 (ru) 2014-12-20
US8961930B2 (en) 2015-02-24
WO2010026388A1 (en) 2010-03-11
AU2009289062B2 (en) 2015-01-22
EP2367816B1 (en) 2016-11-09
US20110195024A1 (en) 2011-08-11
AU2009289062A1 (en) 2010-03-11
JP2012502014A (ja) 2012-01-26
JP5667056B2 (ja) 2015-02-12
CN102171208A (zh) 2011-08-31
MX2011002498A (es) 2011-08-04
KR20110066927A (ko) 2011-06-17

Similar Documents

Publication Publication Date Title
Smith et al. Design, synthesis, and biological characterization of a caspase 3/7 selective isatin labeled with 2-[18F] fluoroethylazide
EP2257315B1 (en) Contrast agents for applications including perfusion imaging
CN111991570A (zh) 一种FAP-α特异性肿瘤诊断SPECT显像剂
CN102686591A (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
KR101879431B1 (ko) 황화수소 검출용 방사성 프로브
CN118955616B (zh) 一种靶向结合成纤维细胞活化蛋白化合物及应用
KR20090130106A (ko) 니트로-이미다졸 저산소증 영상화제
AU2009289062B2 (en) Isatin derivatives for use as in vivo imaging agents
Smith et al. Synthesis and evaluation of C-11, F-18 and I-125 small molecule radioligands for detecting oxytocin receptors
EP3986902B1 (en) Macrocyclic inhibitors of mcl-1
WO2014055505A1 (en) Bodipy dyes for biological imaging
EP3281643A2 (en) Radioactive probe for detecting hydrogen sulfide
EP4590346A1 (en) Fibroblast activation protein (fap) inhibitors, fap conjugates, and diagnostic and therapeutic uses thereof
Karan et al. Activatable near-infrared fluorescence and chemical exchange saturation transfer MRI multimodal imaging probe for tumor detection in vitro and in vivo
Kwon et al. Synthesis and evaluation of multivalent nitroimidazole-based near-infrared fluorescent agents for neuroblastoma and colon cancer imaging
Lo et al. Radiolabelling Pt-based quadruplex DNA binders via click chemistry
US8329686B2 (en) Isatin analogues and uses therefor
JP2019043882A (ja) 代替抗癌剤の治療効果予測剤
Prause et al. Synthesis, in vitro and in vivo evaluation of 18F-fluoronorimatinib as radiotracer for Imatinib-sensitive gastrointestinal stromal tumors
Green et al. Mitochondria and Neuromast Tagging With Fluorescent Gallium‐Triapine Analogues: In Cellulo MP FLIM and Zebrafish Live Imaging
Begoyan Exploring Substrate Specificity of Fructose Transporters En Route to Glut Specific Probes for Biochemical and Biomedical Applications
Li Novel TSPO ligands to facilitate rapid tracer discovery and as precision imaging diagnostics of cancer
Chitneni et al. ÔØ Å ÒÙ× Ö ÔØ
Schaffer et al. Development and biological evaluation of [18F] FMN3PA & [18F] FMN3PU for leucine-rich repeat kinase 2 (LRRK2) in vivo PET imaging
Estrada Synthesis of11C-labeled Sulfonyl Carbamates through a Multicomponent Reaction Employing Sulfonyl Azides, Alcohols, and [11C] CO

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140903

FZDE Discontinued

Effective date: 20160906